Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Generalized Anxiety Disorder
Interventions: SYN111, Placebo; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Atlanta, Georgia • Dayton, Ohio

Conditions: HIV Seronegativity, AIDS Vaccines
Interventions: VRC-HIVDNA009-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: CS8080, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Non-Alcoholic Steatohepatitis
Interventions: EDP-305 Dose 1, EDP-305 Dose 2, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 70
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Post Traumatic Stress Disorder, Trauma
Interventions: Beetroot Juice, Placebo Juice; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Upper Limb Spasticity
Interventions: DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 26
States / cities: Downey, California • Fountain Valley, California • Long Beach, California + 22 more

Conditions: Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 13
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more

Conditions: Photosensitive Epilepsy
Interventions: Valproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Chesterfield, Missouri • Nashville, Tennessee

Conditions: Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions: IFX-1 low dose, IFX-1 high dose, Placebo; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 33
States / cities: Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Alcoholism
Interventions: Topiramate; Drug
Lead sponsor: Bankole Johnson; Other
Eligibility: 21 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: Melatonin, Placebo; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Oxidative Stress
Interventions: 6 mg xanthohumol per day, 12 mg xanthohumol per day, 24 mg xanthohumol per day, Placebo; Drug
Lead sponsor: Oregon State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Bowel Dysfunction, Constipation
Interventions: Alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 143
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more

Conditions: Methamphetamine or Cocaine Dependence
Interventions: Doxazosin extended release; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Digestive System Disease
Interventions: Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo; Drug
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: 10% N2O, 20% N2O, 30% N2O, 40% N2O; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 37 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Crohn Disease
Interventions: Ozanimod, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 107
States / cities: Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Fountain Valley, California • Mather, California • Sacramento, California + 28 more

Conditions: Healthy Adults
Interventions: Glutathione supplementation, Gluthathione peroxidases, Placebo; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 30 Years to 79 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Dementia
Interventions: 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED; Device
Lead sponsor: Quietmind Foundation; Other
Eligibility: 50 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Plymouth Meeting, Pennsylvania

Conditions: Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions: Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant, Placebo; Device · Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Shy-Drager Syndrome, Multiple System Atrophy
Interventions: Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water, Placebo + 480 ml water (optional), Placebo + 50 ml water (optional); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions: Mepivacaine, Saline, Perifemoral Injection of Local Anesthetic; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

HIV-1 Vaccine Test in Uninfected Adult Volunteers

Effects of CS-8080 in Healthy Volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Effect of Valproic Acid Concentration on Photic Response

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

New Medications to Treat Alcohol Dependence

Sleep, Diabetic Retinopathy and Melatonin

Xanthohumol and Prevention of DNA Damage

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Doxazosin for Psychostimulant Dependence

Gastric Gluten-Degradation Activity of PvP001

Effects of Nitrous Oxide: A Dose-Response Analysis - 5

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Oral Glutathione Supplementation on the Levels of Blood Glutathione

Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Water and Sudafed in Autonomic Failure

Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension